Primary Prevention of HPV through Vaccination: Update on the Current Global Status
Ten years after the first licencing of a prophylactic human papillomavirus (HPV) vaccine, this paper reviews global information on programme coverage, as reported to WHO and from the published and grey literature. As of May 2016, 74 countries report that the HPV vaccine is on the national schedule or reimburse vaccine costs. We also summarise the latest available information on programme implementation, vaccine effectiveness, the nine-valent HPV vaccine and the accumulated safety experience with HPV vaccines.
KeywordsHuman papillomavirus HPV vaccine Immunisation Vaccine coverage
Compliance with Ethical Standards
Conflict of Interest
Julia M. L. Brotherton declares to have been an investigator on investigator-designed unrestricted epidemiological research grants partially funded through Seqirus/Merck, but has received no personal financial benefits.
Patrick L.F. Zuber and Paul J. N. Bloem declare no conflict of interest.
The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the World Health Organization.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62. doi: 10.4161/hv.29532.CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Apter D, Wheeler CM, Paavonen J, Castellsague X, Garland SM, Skinner SR, et al. Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomised, double-blind PATRICIA trial. Clin Vaccin Immunol. 2015;22(4):361–73.CrossRefGoogle Scholar
- 4.•Nygård M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol. 2015;22:943–8. doi: 10.1128/CVI.00133-15. Study that suggests over 9 years of sustained antibodies are induced by the quadrivalent HPV vaccine.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.•Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. The Lancet Oncology. 2015;17(1):67–77. First cohort study to suggest a protective effect of one dose of quadrivalent HPV vaccine on HPV infection. Further data from this study are awaited to confirm these initial findings.CrossRefPubMedGoogle Scholar
- 9.•Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04 adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine Trial and the PATRICIA Trial. Lancet Oncol. 2015;16(7):775–86. Analysis suggesting equivalent efficacy to three doses from one or two doses of bivalent HPV vaccine.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.•Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis. Br J Cancer advance online publication. 2016. doi: 10.1038/bjc.2016.97. First analysis to document population-based impact of one or two doses of bivalent HPV vaccine on HPV infection.Google Scholar
- 15.Perkins RB, Legler A, Hanchate A. Trends in male and female genital warts among adolescents in a safety-net health care system 2004–2013: correlation with introduction of female and male human papillomavirus vaccination. Sex Transm Dis. 2015;42(12):665–8. doi: 10.1097/OLQ.0000000000000369.CrossRefPubMedGoogle Scholar
- 19.Mollers M, King AJ, Knol MJ, Scherpenisse M, Meijer CJ, van der Klis FR, et al. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: results from a longitudinal Dutch cohort study. Vaccine. 2015;33(23):2678–83. doi: 10.1016/j.vaccine.2015.04.016.CrossRefPubMedGoogle Scholar
- 24.Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016. doi: 10.1016/j.ajog.2016.02.021.PubMedGoogle Scholar
- 25.•Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Eng J Med. 2015;372(8):711–23. RCT analysis of the nine-valent HPV vaccine showing equivalent immunogenicity as quadrivalent vaccine against types 6/11/16/18 and high efficacy against types 31/33/45/52/58.CrossRefGoogle Scholar
- 31.World Health Organization (June 2012). Information sheet. Observed rates of vaccine reactions. Human papilloma virus vaccines. http://www.who.int/vaccine_safety/initiative/tools/HPV_Vaccine_rates_information_sheet.pdf?ua=1. Accessed 10 May 2016.
- 38.Global Advisory Committee on Vaccine Safety, 12–13 June 2007. Wkly Epid Rec 2007; 82: 252–9.Google Scholar
- 42.Global Advisory Committee on Vaccine Safety (GACVS). Report of meeting held 17–18 June 2009. Wkly Epid Rec. 2009;84:325–32.Google Scholar
- 48.Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 2011;7(12):1343–58.CrossRefPubMedGoogle Scholar
- 51.National Pharmaceutical Control Bureau, Ministry of Health Malaysia. MADRAC Bulletin April 2011. http://bpfk.moh.gov.my/images/Publications/Newsletter_MADRAC_Bulletin/MADRAC_BULLETIN_APRIL_2011.pdf. Accessed 10 May 2016.
- 55.•Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54–61. Methodologically strong population-based two-country study including 4 million women demonstrating no increase in risk of multiple sclerosis in women vaccinated against HPV.CrossRefPubMedGoogle Scholar
- 57.Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.CrossRefPubMedPubMedCentralGoogle Scholar
- 58.Agence nationale de sécurité des medicaments et des produits de santé. Vaccins anti-HPV et risque de maladies autoimmunes: étude pharmacoépidémiologique. http://ansm.sante.fr/content/download/80841/1023043/version/1/file/Ansm_Gardasil-Hpv2_Rapport_Septembre-2015.pdf. Accessed 10 May 2016.
- 61.WHO/UNICEF Joint reporting Form, 1 May 2016. http://www.who.int/immunization/monitoring_surveillance/data/en/. Accessed 15 May 2016.
- 62.WHO V3P. The Vaccine Product, Price and Procurement (V3P) Project. http://www.who.int/immunization/programmes_systems/procurement/v3p/en/. Accessed 19 April 2016.
- 63.PAHO/WHO. Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Washington DC, March 20, 2014. http://www.paho.org/hq/index.php?option=com_content&view=article&id=9394:el-80-de-las-ninas-adolescentes-de-las-americas-tendra-acceso-a-la-vacuna-contra-el-vph-tras-haberse-introducido-en-brasil-&catid=740:news-press-releases&Itemid=1926&lang=en. Accessed May 2016.
- 64.World Health Organization, Department of Immunization, Vaccines and Biologicals. Projections of national annual population 5–74 of age by single year of age and sex, 2010–2020. Geneva; 2016 update. http://www.who.int/immunization/diseases/hpv/UN_population_estimates_9-13_year-old_cohort/en/. Accessed 15 May 2016.
- 65.World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Weekly Epidemiologic Record WER. 2014;43(89):465–92. Accessed 15 May 2016 http://www.who.int/wer/2014/wer8943.pdf?ua=1.
- 66.BYJU’S, December 28, 2015. http://byjus.com/free-ias-prep/check-cervical-cancer-govt-plans-launch-hpv-vaccine. Accessed 17 May 2016.
- 67.Indian Express, 1 March 2016. http://indianexpress.com/article/cities/delhi/delhi-first-state-to-launch-hpv-vaccine-as-public-health-programme-in-schools/ Accessed 17 April 2016.
- 72.UK Government. JCVI interim position statement on HPV vaccination of men who have sex with men (MSM). 2015. Accessed May 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/373531/JCVI_interim_statement_HPV_vacc.pdf.Google Scholar
- 77.Rehn M, Uhnoo I, Kühlmann-Berenzon S, Wallensten A, Sparén P, Netterlid E. Vaccine uptake after school-based delivery—a county-level evaluation of the implementation highest strategies for HPV catch-up vaccination in Sweden. PLoS ONE. 2016;11(3):e0149857. doi: 10.1371/journal.CrossRefPubMedPubMedCentralGoogle Scholar
- 78.World Health Organization. Scaling-up HPV vaccine introduction. Geneva, 2016 (in press). http://www.who.int/immunization/diseases/hpv/resources/en/index.html.
- 80.Pharmaceutical Benefits Scheme. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, solution for injection, 0.5 mL, solution for injection pre-filled syringe single dose, Gardasil®—November 2011. Public Summary document. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-11/pbac-psd-quadrivalent-nov11. Accessed 15 May 2016.
- 81.European Centre for Disease Control and Prevention. HPV vaccine schedules in European countries. 2016. http://vaccine-schedule.ecdc.europa.eu/pages/scheduler.aspx. Accessed 15 May 2016.
- 83.Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis. 2016;16:52. doi: 10.1186/s12879-016-1347-z.CrossRefPubMedPubMedCentralGoogle Scholar
- 87.•PATH, LSTHM. HPV vaccine lessons learned. http://www.rho.org/HPVlessons/. Accessed 17 April 2016. Comprehensive and easily digestible summary (videos, briefs and slides) of a comprehensive review of HPV vaccine delivery experiences across 37 low- and middle-income countries.
- 92.World Health Organization, Department of Immunization, Vaccines and Biologicals. Haemophilus influenzae type b (Hib). http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/sentinel/Hib/en/. Accessed 15 May 2016.
- 93.World Health Organization (2011) Global vaccine action plan. http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/. Accessed 15 May 2016.